Communiqués de presse

(Documents disponibles en anglais seulement)

avr. 12, 2024

   SUNSHINE BIOPHARMA ANNOUNCES REVERSE STOCK SPLIT

avr. 01, 2024

   Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

févr. 15, 2024

   Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

févr. 13, 2024

   Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

déc. 04, 2023

   SUNSHINE BIOPHARMA MOVES PRINCIPAL OFFICE TO NEW YORK CITY

nov. 13, 2023

   SUNSHINE BIOPHARMA REPORTS 2023 THIRD QUARTER RESULTS: REVENUES UP SIGNIFICANTLY OVER LAST YEAR DUE TO A KEY ACQUISITION

sept. 21, 2023

   SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION TO ACHIEVE NASDAQ MINIMUM BID COMPLIANCE

août 11, 2023

   SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600%

mai 16, 2023

   SUNSHINE BIOPHARMA ANNOUNCES CLOSING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

mai 12, 2023

   SUNSHINE BIOPHARMA ANNOUNCES PRICING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT THE MARKET

mai 11, 2023

   SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%

avr. 05, 2023

   SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

févr. 28, 2023

   SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT

févr. 10, 2023

   SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND

jan. 19, 2023

   SUNSHINE BIOPHARMA ANNOUNCES SHARE REPURCHASE PROGRAM

déc. 20, 2022

   SUNSHINE BIOPHARMA’S ANNUAL LETTER TO SHAREHOLDERS

nov. 16, 2022

   SUNSHINE BIOPHARMA ENTERS INTO COLLABORATION WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT

oct. 20, 2022

   SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE

juill. 28, 2022

   SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA

avr. 28, 2022

   Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

avr. 26, 2022

   Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

avr. 25, 2022

   Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules…

avr. 05, 2022

   Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

mars 14, 2022

   Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

mars 10, 2022

   Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market

févr. 25, 2022

   SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA

févr. 15, 2022

   Sunshine Biopharma Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

déc. 22, 2021

   Sunshine Biopharma Announces $1,361,000 in Debt Reduction

nov. 03, 2021

   SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS

oct. 06, 2021

   Sunshine Biopharma Files a Patent Application Covering mRNA Molecules…

août 12, 2021

   SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN

juill. 27, 2021

   Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement

juill. 20, 2021

   SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL

juill. 08, 2021

   Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer

juin 09, 2021

   SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED

mai 20, 2021

   SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

mai 13, 2021

   SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING

mai 04, 2021

   SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

avr. 23, 2021

   SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT

avr. 22, 2021

   RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA

mars 23, 2021

   SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT

mars 11, 2021

   SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033

mars 04, 2021

   Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a And Initiates QA/QC Testing

mars 01, 2021

   Sunshine Biopharma Launches Online Store for Its Science-Based Nutritional Supplements

févr. 18, 2021

   Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast

févr. 10, 2021

   SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY

févr. 04, 2021

   SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS

févr. 02, 2021

   SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033

jan. 27, 2021

   SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB

jan. 14, 2021

   SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

déc. 22, 2020

   SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK

déc. 08, 2020

   SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS

déc. 03, 2020

   SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET

déc. 01, 2020

   SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 plus FINANCING FOR CORONAVIRUS TREATMENT

nov. 24, 2020

   SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY

nov. 18, 2020

   Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound

nov. 10, 2020

   Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East

oct. 26, 2020

   SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

oct. 19, 2020

   SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG

oct. 07, 2020

   SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND

sept. 15, 2020

   SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

août 25, 2020

   SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE

juin 03, 2020

   SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT

nov. 06, 2019

   SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT

oct. 17, 2019

   SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER<

sept. 03, 2019

   Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement

mai 28, 2019

   In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca

mai 16, 2019

   Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com

mars 12, 2019

   SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA

févr. 04, 2019

   Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033

déc. 17, 2018

   Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company’s First Over The Counter Essential Micronutrient

déc. 12, 2018

   Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug

sept. 14, 2018

   Sunshine Biopharma Announces $10 Million Equity Financing

août 16, 2018

   Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.

juin 18, 2018

   Sunshine Biopharma Launches Microbiology Testing Service

mai 10, 2018

   Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing

jan. 04, 2018

   Sunshine Biopharma Completes the Acquisition of Atlas Pharma

sept. 05, 2017

   Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million…

juin 26, 2017

   Sunshine Biopharma Releases Results of Independent Valuation

juin 19, 2017

   Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License

jan. 11, 2017

   Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing

déc. 09, 2016

   Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma

juin 30, 2016

   Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH

mai 11, 2016

   Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company’s First Generic Drug For Treatment Of Breast Cancer

mars 15, 2016

   Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound

déc. 28, 2015

   Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound

oct. 09, 2015

   Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a

août 04, 2015

   Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a…

mai 26, 2015

   Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland

mars 24, 2015

   Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India

févr. 25, 2015

   Sunshine Biopharma Announces Change To Its Board Of Directors And Officers

jan. 20, 2015

   Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound

nov. 19, 2014

   Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a

nov. 03, 2014

   Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a

oct. 14, 2014

   Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations

oct. 01, 2014

   Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License

sept. 03, 2014

   Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound

août 21, 2014

   Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical…

août 11, 2014

   Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations

juin 09, 2014

   Sunshine Biopharma’s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells

mai 12, 2014

   Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada

avr. 29, 2014

   Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II

avr. 07, 2014

   Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro

mars 31, 2014

   Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise

févr. 14, 2014

   Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a…

juin 19, 2013

   Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling

juin 04, 2013

   Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells

mai 01, 2013

   Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers

avr. 09, 2013

   Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations

mars 14, 2013

   Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant…

févr. 26, 2013

   Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a

jan. 15, 2013

   Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a…

déc. 10, 2012

   Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells

déc. 04, 2012

   Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a

nov. 27, 2012

   Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents

nov. 13, 2012

   Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a

oct. 09, 2012

   Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a

sept. 25, 2012

   Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in Oct. Issue of ANTICANCER RESEARCH

sept. 20, 2012

   Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials

sept. 13, 2012

   Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a

sept. 04, 2012

   Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of…

août 15, 2012

   Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal

août 03, 2012

   BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report

juill. 30, 2012

   Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

juill. 24, 2012

   Biotech Investor Alert: CFO of Sunshine Biopharma Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a

juill. 19, 2012

   Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)

juill. 11, 2012

   Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a

juill. 02, 2012

   Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound – Adva-27a for Aggressive Forms of Cancer

juin 26, 2012

   Sunshine Biopharma’s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells

mai 22, 2012

   Pharmacokinetics Parameters of Sunshine Biopharma’s Lead Anti-Cancer Compound Exceed Expectations

avr. 09, 2012

   Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound

mars 26, 2012

   Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago

nov. 28, 2011

   Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals

nov. 15, 2011

   Sunshine Biopharma’s Announces Successful Completion of Preclinical Studies for Adva-27a, The Company’s Lead Anti-Cancer Compound

oct. 05, 2011

   Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor

août 30, 2011

   Clearance of Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate

juill. 27, 2011

   Sunshine Biopharma Looking to Mimic Roche’s Billion Dollar Cancer Drug Success

juill. 25, 2011

   Sunshine Biopharma’s Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism

juill. 11, 2011

   Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells

juin 17, 2011

   Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada

avr. 01, 2011

   Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com

mars 27, 2011

   Sunshine Biopharma’s Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays

mars 04, 2011

   CEO CFO Interviews Dr. Steve N. Slilaty

févr. 25, 2011

   Interview with Central NY Business Journal

jan. 26, 2011

   FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1

jan. 21, 2011

   Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement

oct. 26, 2010

   CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.

oct. 13, 2010

   Sunshine Biopharma, Inc. Begins Drug Development Activities

oct. 20, 2009

   Mountain West Business Solutions Acquires Sunshine Biopharma